July 1, 2019
NRG Oncology Broadcast archives are accessible from our website at any time. Please bookmark  this link  for your convenience.

Pre-registration is now Closed! Please register onsite at the meeting.

Registration and meeting information is available on the  NRG Oncology website.


Read more

 
 

Pre-registration is now Closed! Please register onsite at the meeting.

Registration and meeting information is available on the NRG Oncology website.

  

Meeting Highlights

  • Patient Reported Outcomes: Upping the game for PRO methods and design in clinical trials
    NRG Oncology will be holding a workshop at the NRG Semiannual Meeting related to improving statistical methods to meet study goals, analyzing longitudinal PRO data as well as a panel discussion with NCORP PIs. This session will be held on Thursday, July 18, 2019 from 1-5pm and will be open to all attendees. The agenda can be found here.
  • Summer Symposium: Thursday, July 18 -  8am-3pm Read more
  • Scientific Session: Friday, July 19 -  8-10am Read more
  • Health Disparities Workshop Special Session: Sexual and Gender Minority Related Activities at the NIH - Friday, July 19 - 10-11:30am Read more
  • Social Media Workshop: Friday, July 19 - 11:30am -12:30pm Read more

SAVE THE DATE: Information Session for NRG-BN006
NRG Oncology will be holding an information session for NRG-BN006:  A Phase II/III Randomized, Open-Label Study of Toca 511, A Retroviral Replicating Vector, Combined with Toca FC with Temozolomide and Radiation Followed by Adjuvant Temozolomide and Toca FC Compared to Temozolomide and Radiation Followed by Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma on Friday, July 19, 2019 from 10:30-11am ET. The information session will be held at the NRG Oncology Semiannual Meeting in Philadelphia and is open to all attendees. More information on the information session agenda and room location will be released soon. Please contact Erin Moye at moyee@nrgoncology.org for any questions at this time.

 

SAVE THE DATE: Kick-Off Session for NRG-GU007

NRG Oncology will be holding a kick-off session for NRG-GU007: Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (with Initial Phase I) on Friday, July 19, 2019 from 11am-12pm ET. The information session will be held at the NRG Oncology Semiannual Meeting in Philadelphia and is open to all attendees. More information on the kick-off session agenda and room location will be released soon. Please contact Erin Moye at moyee@nrgoncology.org for any questions.
 

SAVE THE DATE: Kick-Off Session for NRG-LU003

NRG Oncology will be holding a kick-off session at the NRG Oncology Semiannual Meeting for NRG-LU003 “A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol.” The session will be held on Saturday, July 20, 2019 from 10:30-11:30am ET and will be open to all attendees. More information on the session and agenda are posted here. Please contact Erica Field at fielde@nrgoncology.org for any questions.

 

SAVE THE DATE: Kick-Off Session for NRG-LU005
NRG Oncology will be holding an kick-off session for NRG-LU005: Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab on Friday, July 19, 2019 from 3-4pm ET. The kick-off session will be held at the NRG Oncology Semiannual Meeting in Philadelphia and is open to all attendees. More information on the kick-off session agenda and room location will be released soon.  Please contact Erin Moye at moyee@nrgoncology.org for any questions.

SAVE THE DATE: Information Session for SWOG/NRG S1806

NRG Oncology will be holding an information session for SWOG/NRG S1806: “Phase III Trial of Concurrent Chemoradiation With or Without Atezolizumab for Localized Muscle Invasive Bladder Cancer: SWOG/NRG Intergroup Trial (S1806)” on Friday, July 19, 2019 from 12:00 – 1:00 PM ET.  The information session will be held at the NRG Oncology Semiannual Meeting in Philadelphia and is open to all attendees.  Box lunches will be provided to those who register for the session prior to July 9th.  To reserve a box lunch please register at: https://www.surveymonkey.com/r/SWOG-NRG_S1806 .  Tickets for those who pre-register will be included in your meeting registration package.  More information on the information session agenda and room location will be released soon. Please contact Treena Davis-Trotmanat Davis-TrotmanT@NRGOncology.org for any questions.

 

Social Media Workshop 1-on-1's at #NRG19

Are you ready to get started on Twitter?  Let our social media experts show you how simple it is to set up a new account or make your existing account more engaging. At #NRG19, we have scheduled two Social Media 1-on-1 Workshops where our Twitter experts will be on hand to show you the how-to's of Twitter. If you are interested in learning more about tweeting, retweeting, hashtags, following, and more, stop by during one of the following sessions and bring your smartphone &/or laptop. No previous social media experience required! Friday, July 19, 12:30-1pm and Saturday, July 20, 10-11am. Meet the experts here


CLOSURES AND SUSPENSIONS

GENITOURINARY

RTOG 0924: Closure Memorandum dated June 24, 2019; the trial has met its target accrual and will close to accrual at 5 PM ET today. (posted on CTSU)


AMENDMENTS

SARCOMA

NRG-DT001: Amendment 5; version date May 29, 2019.

Note: Per NCI’s Uniform Document Posting Policy for CIRB-Reviewed Studies: The protocol, consent, and summary of changes are posted to the CIRB tab of the CTSU website. Since this study is open only to NRG member sites, all other protocol-related documents are posted on the  NRG Oncology website.

 

CANCER PREVENTION & CONTROL

NRG-CC004 (NCORP and Limited institutions): Amendment 3, version date June 7, 2019

Note: Per NCI’s Uniform Document Posting Policy for CIRB-Reviewed Studies: The protocol, consent, and summary of changes are posted to the CIRB tab of the CTSU website. Since this study is open only to NRG member sites, all other protocol-related documents are posted on the  NRG Oncology website.


OTHER PROTOCOL NOTICES

1. BREAST

NRG-BR004: Bioclinica Site Manual (posted to CTSU).

NRG-BR004: Updated Pathology Instructions (posted to CTSU).


2. GYNECOLOGIC

NRG-GY007: CT Assessment Date Calculators

Two calculators have been posted for the Phase II portion of NRG-GY007. One is for patients who undergo TRS; one is for patients who do not undergo TRS. These calculators can be found on the NRG Oncology Protocol Table: NRG-GY007 > Correspondence and Instructions > Other

 

NRG-GY009: Block Submission Reminder memo (posted on CTSU)

 

Form TR for Biospecimens Shipped to NRG Biospecimen Bank-Columbus Read more

 

Biospecimen Bank-Columbus & SDMC Undergoing Refurbishment Read more


3. LUNG

NRG-LU003: Participant brochure approved by the CIRB and posted on CTSU.

 

4. DMC MEETING EXCERPTS

NRG Oncology DMC (Panel A and Panel B) Meeting Summaries/Excerpts have been posted. For studies on the CTSU menu, excerpts can be found on individual protocol pages on the CTSU website. (Note: A list of studies with excerpts posted to CTSU can be found on the DMC page on the NRG Oncology and under Protocol Updates on CTSU website.) Excerpts for studies that are not on the CTSU menu are posted on the DMC page on the NRG Oncology website (login required).


5. VTOC TRAINING

The VTOC Webinar Training Series schedule and registration is available for NRG Oncology Research Associates working on RTOG 0924, RTOG 0920, NRG-HN001, NRG-HN002, NRG-CC003, and NRG-CC004. The VisionTree staff will be at the round table session during the NRG semiannual meeting on July 18. Please stop by to learn more about VTOC.

 

DRUG SAFETY UPDATES

Safety updates have been issued for the following studies:

 

DRUG NAME

PROTOCOL

WEBSITE FOR SAFETY REPORTS

Bevacizumab

GOG-0213

GOG-0262

NRG

CTSU

Ipilimumab

NRG-BN002

NRG-GY003

NRG

NRG

Nivolumab

NRG-BN002

NRG-GY003

NRG

NRG

Pembrolizumab

NRG-GI002

NRG-GY016

NRG-HN003

CTSU

CTSU

NRG

 

 

JULY 4th HOLIDAY CLOSURES
The NRG Oncology Operations Offices, Statistics and Data Management Centers (SDMCs), Biospecimen Banks, Serum Bank and McKesson's Clinical Research Services will be closed on Thursday, July 4 in observance of Independence Day. The Philadelphia East Operations, Philadelphia West Operations, and Philadelphia SDMC Offices will also be closed on Friday, July 5. More information about these closures and shipping information for the banks is posted on the  NRG Oncology website under "News."

NRG-BR002: The Kuhn Laboratory at USC will be closed Thursday, July 4th – Friday, July 5th for Independence Day. Please reschedule all draws for Wednesday July 3rd due to inability to receive samples on the 4th. Please schedule specimen collection accordingly around this time. The lab will resume processing samples on Monday, July 8th. For further questions please contact Xiomara at the Kuhn Laboratory at xvillase@usc.edu or 213-740-9614.

NRG Oncology is pleased to report the scientific articles and abstracts that have appeared or have been presented during the previous week. This publications report includes links, when available, to the article, PubMed abstract, or association abstract.

JOURNAL ARTICLES

Rodriguez GC, Kauderer J, Hunn J, Thaete LG, Watkin WG, Russell S, Yozwiak M, Basil J, Hurteau J, Lele S, Modesitt SC, Zivanovic O, Zhang HH, Bartels PH, Alberts DS. Phase II Trial of Chemopreventive Effects of Levonorgestrel on Ovarian and Fallopian Tube Epithelium in Women at High Risk for Ovarian Cancer: An NRG Oncology Group/GOG Study. Cancer Prev Res (Phila). 2019 Jun;12(6):401-412. doi: 10.1158/1940-6207.CAPR-18-0383. Epub 2019 Apr 23. PubMed PMID: 31015198.  Read more


ACCEPTED MEETING ABSTRACTS

Kim I, Winter KA, Peereboom DM, De Los Santos JF, Sperduto PW, Ogunleye T, Boulter D, White JR, Mehta MP. NRG/RTOG 1119: Phase II randomized study of whole brain radiotherapy/stereotactic radiosurgery in combination with concurrent lapatinib in patients with brain metastasis from HER2-positive breast cancer - A collaborative study of NRG Oncology and KROG.  SNO Inaugural Conference on Brain Metastases.  Aug 16, 2019.  Poster.

Tome W, Deshmukh S, Gondi V, Brown P, Wefel JS, Bruner D, Bovi JA, Robinson C, Khuntia D, Grosshans D, Konski A, Roberge D, Kundapur V, Devisetty K, Shah S, Usuki K, Anderson BM, Mehta MP, Kachnic LA. NRG Oncology CC001: A phase III trial of hippocampal avoidance in addition to whole-brain radiotherapy (WBRT) plus memantine to preserve neurocognitive function in patients with brain metastases (BM). SNO Inaugural Conference on Brain Metastases.  Aug 16, 2019. RADI-11.  Oral presentation.

 


PUBLICATIONS REMINDERS

Please note the following upcoming meeting and abstract submission deadline dates

Upcoming Meetings

American Association of Physicists in Medicine (AAPM); Jul 14-18, 2019; San Antonio, TX

American Society for Radiation Oncology (ASTRO); Sep 15-18, 201 9; Chicago, IL


International Gynecologic Cancer Society (IGCS)
; Sep 19-20, 2019; Rio de Janeiro, Brazil


Society for Neuro -Oncology (SNO) Inaugural Conference on Brain Metastases
; Aug 16-17, 2019; New York City, NY

 

Upcoming Abstract Submission Deadlines

European Society for Medical Oncology (ESMO); Sep 27-Oct 1, 2019; Barcelona, Spain; LBA Aug 21, 2019 9:00 pm CEST

San Antonio Breast Cancer Symposium (SABCS); Dec 10-14, 2019; San Antonio, TX; due to publications committee Jun 24, 2019; meeting submission deadline Jul 8, 2019

NRG Oncology is proud to be an active participant of #CancerMoonShot.
This message was sent from NRG-Broadcasts@NRGOncology.org to NRG-Broadcasts@NRGOncology.org
Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103


Update Profile/Email Address | Forward Email | Report Abuse